Phospho-SRC (Tyr418) Monoclonal Antibody (SC1T2M3), eBioscience™

Product Details	
Size	100 µg
Species Reactivity	Human, Mouse
Published Species	Human, Mouse
Host/Isotype	Mouse / IgG2b, kappa
Class	Monoclonal
Type	Antibody
Clone	SC1T2M3
Conjugate	Unconjugated
Form	Liquid
Concentration	0.5 mg/mL
Purification	Affinity chromatography
Storage buffer	PBS, pH 7.2
Contains	0.09% sodium azide
Storage conditions	4° C
RRID	AB_2572916

Applications	Tested Dilution	Publications
Western Blot (WB)	Assay-Dependent	-
Immunohistochemistry (IHC)	-	1 Publication
Immunocytochemistry (ICC/IF)	-	1 Publication
Flow Cytometry (Flow)	-	1 Publication
Miscellaneous PubMed (Misc)	-	1 Publication

Product Specific Information

Description: This SC1T2M3 monoclonal antibody recognizes human and mouse Src tyrosine kinase (also known as ASV, c-src, c-SRC, p60-Src, pp60c-src, Proto-oncogene c-Src, Proto-oncogene tyrosine-protein kinase Src, SRC1) when phosphorylated on tyrosine 418 (Y418). Autophosphorylation of Src at Y418 in the catalytic domain is required for full catalytic activity of this kinase. Src is a non-receptor tyrosine kinase involved in signal transduction in numerous biological systems and is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors. Aberrant Src activity has been implicated in the development of numerous types of cancer. Due to the sequence homology surrounding Src Y418, this SC1T2M3 clone is predicted to cross-react with many Src family kinases including Src, Lck, Fyn, and Lyn.

Specificity of this SC1T2M3 clone was determined by ELISA, flow cytometry, and western blotting.

Applications Reported: This SC1T2M3 antibody has been reported for use in western blotting. (Fluorochrome-conjugated SC1T2M3 is recommended for use in intracellular flow cytometry.).

Applications Tested: This SC1T2M3 antibody has been tested by immunoblotting of staurosporine-treated Jurkat cells. This can be used at less than or equal to 5 µg/mL. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Purity: Greater than 90%, as determined by SDS-PAGE.

Aggregation: Less than 10%, as determined by HPLC.

Filtration: 0.2 µm post-manufacturing filtered.

Product Images For Phospho-SRC (Tyr418) Monoclonal Antibody (SC1T2M3), eBioscience™



Phospho-SRC (Tyr418) Antibody (14-9034-82) in WB
Immunoblotting of reduced lysates from Jurkat T cells left untreated (lane 1), treated with hydrogen peroxide-activated sodium pervanadate (lane 2), or treated with staurosporine (lane 3) using 5 µg/mL of Anti-Human/Mouse phospho-Src (Y418) Purified.

4 References

Immunohistochemistry (1)

Nature cardiovascular research

Sinusoidal and lymphatic vessel growth is controlled by reciprocal VEGF-C-CDH5 inhibition.

"14-9034-82 was used in Immunohistochemistry-immunofluorescence to establish an essential role for VEGF-C /VEGFR3 signaling during sinusoidal vascular growth, identify VE-cadherin as a powerful negative regulator of VEGF-C signaling that acts through both VEGFR3 and VEGFR2 receptors, and suggest that negative regulation of VE-cadherin is required for effective VEGF-C/VEGFR3 signaling during growth of sinusoidal and lymphatic vessels."

Authors: Sung DC,Chen M,Dominguez MH,Mahadevan A,Chen X,Yang J,Gao S,Ren AA,Tang AT,Mericko P,Patton R, Lee M,Jannaway M,Nottebaum A,Vestweber D,Scallan JP,Kahn ML

Year
2022

Species
Human
Mouse

Dilution
1:100
1:100

Immunocytochemistry (1)

Nature cardiovascular research

Sinusoidal and lymphatic vessel growth is controlled by reciprocal VEGF-C-CDH5 inhibition.

"14-9034-82 was used in Immunohistochemistry-immunofluorescence to establish an essential role for VEGF-C /VEGFR3 signaling during sinusoidal vascular growth, identify VE-cadherin as a powerful negative regulator of VEGF-C signaling that acts through both VEGFR3 and VEGFR2 receptors, and suggest that negative regulation of VE-cadherin is required for effective VEGF-C/VEGFR3 signaling during growth of sinusoidal and lymphatic vessels."

Authors: Sung DC,Chen M,Dominguez MH,Mahadevan A,Chen X,Yang J,Gao S,Ren AA,Tang AT,Mericko P,Patton R, Lee M,Jannaway M,Nottebaum A,Vestweber D,Scallan JP,Kahn ML

Year
2022

Species
Human
Mouse

Dilution
1:100
1:100

Flow Cytometry (1)

Oncotarget

Drug conjugated nanoparticles activated by cancer cell specific mRNA.

"14-9034-82 was used in Flow Cytometry to develop a customisable approach to cancer therapy in which a gold nanoparticle delivers a drug that is selectively activated within the cancer cell by the presence of an mRNA unique to the cancer cell."

Authors: Gossai NP,Naumann JA,Li NS,Zamora EA,Gordon DJ,Piccirilli JA,Gordon PM

Year
2016

Species
Human

Miscellaneous PubMed (1)

Circulation research

Hyperreactivity of junctional adhesion molecule A-deficient platelets accelerates atherosclerosis in hyperlipidemic mice.

Authors: Karshovska E,Zhao Z,Blanchet X,Schmitt MM,Bidzhekov K,Soehnlein O,von Hundelshausen P,Mattheij NJ, Cosemans JM,Megens RT,Koeppel TA,Schober A,Hackeng TM,Weber C,Koenen RR

Year
2015